Dx by dt: diagnostic intent over time
This article was originally published in Scrip
If Roche acquires Illumina, as it seems fairly intent on doing despite repeated messages of rejection from the smaller company, then it will not be the first company to acquire a genome sequencing firm. It will however be the first pharmaceutical company to acquire two such companies and will in effect have cornered the market in high-throughput genome technology. And that is important for positioning Roche front and centre in oncology.